Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price ...

Becton, Dickinson and Company announced it repurchased $750M in BD stock to date in FY25. In addition, the board has authorized the company to ...

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $243.45 which represents a slight increase of $2.98 or 1.24% from the prior close of $240.47. The stock opened at $239 and ...

Atomi Financial Group Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 25.3% in the ...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, ...

Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 98.2% in the ...

Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Piper Sandler's analysts increased the price target for Becton Dickinson (NYSE:BDX) shares to $280 from $275, while ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...